Journal of Acupuncture and Tuina Science

, Volume 15, Issue 2, pp 88–93 | Cite as

Effect of electroacupuncture on gastric motility, expressions of ghrelin and GHSR mRNA in gastric antrum tissue of diabetic gastroparesis rats

  • Yan Peng (彭艳)
  • Ya-ping Lin (林亚平)
  • Feng-e He (贺凤娥)
  • Quan-quan Wan (万荃荃)
  • Wen Chen (陈文)
  • Qin Liu (刘琴)
  • Shou-xiang Yi (易受乡)
Basic Study
  • 20 Downloads

Abstract

Objective

To explore the action mechanism of electroacupuncture (EA) in improving the gastric motility of rats with diabetic gastroparesis (DGP).

Methods

Forty-eight healthy Sprague-Dawley (SD) rats were randomly assigned into four groups: a normal group (group A), a model group (group B), a group of EA at acupoints (group C), and a group of EA at non-acupoints (group D), 12 rats in each group. The animal model of DGP was established by intraperitoneal injection of streptozotocin (STZ) plus high glucose and fat diet. The blood glucose, urine glucose and gastric emptying rate (GER) were observed. The content of insulin (INS) in serum and ghrelin in gastric antrum tissue were detected by enzyme linked immunoassay (ELISA). The expression of growth hormone secretagogue receptor mRNA (GHSR mRNA) in gastric antrum tissue was detected by real-time fluorescent quantitative polymerase chain reaction (PCR).

Results

Compared with group A, blood glucose and urine glucose increased significantly (P<0.01), GER, content of serum insulin, the content of ghrelin and expression of GHSR mRNA in gastric antrum tissue decreased significantly (P<0.05 or P<0.01) in group B. Compared with group B, blood glucose and urine glucose decreased significantly (P<0.05), GER, the content of insulin in serum, the content of ghrelin and expression of GHSR mRNA in gastric antrum tissue increased significantly (P<0.05 or P<0.01) in group C.

Conclusion

EA at acupoints can down-regulate the content of blood and urine sugar, and promote gastric emptying, which is possibly related to the regulation of serum insulin, and the expressions of ghrelin and GHSR mRNA in gastric antrum.

Keywords

Acupuncture Therapy Electroacupuncture Ghrelin Receptors Ghrelin Insulin Diabetes Complications Gastroparesis Rats 

电针对糖尿病胃轻瘫大鼠胃动力及胃窦组织Ghrelin和GHSR mRNA表达的影响

摘要

目的

探讨电针改善糖尿病胃轻瘫(DGP)大鼠胃动力的机制。

方法

将48只健康SD大鼠随机分为4组, 即 空白对照组(A组)、模型组(B组)、电针穴位组(C组)和电针非穴组(D组), 每组12只。采用腹腔注射链脲佐菌素配合 高糖高脂饮食建立大鼠DGP模型。观察大鼠血糖、尿糖值和胃排空率, 采用酶联免疫法检测血清胰岛素含量、胃 窦组织促生长素(ghrelin)含量, 实时荧光定量PCR法测定胃窦部生长素促分泌激素受体基因(GHSR mRNA)的表达。

结果

与空白组比较, 模型组大鼠血糖、尿糖值显著增高(P<0.01), 胃排空率、血清胰岛素水平、胃窦ghrelin及 GHSR mRNA表达显著降低(P<0.05或P<0.01); 经电针穴位后, 血糖、尿糖值显著降低(P<0.05), 胃排空率、血清 胰岛素水平、胃窦ghrelin及GHSR mRNA表达显著增高(P<0.05或P<0.01)。

结论

电针可降低DGP大鼠血糖、尿糖 值, 促进胃排空, 这可能与其调节血清胰岛素含量, 胃窦ghrelin及GHSR mRNA表达有关。

关键词

针刺疗法 电针 胃促生长素 受体 胃促生长素 胰岛素 糖尿病并发症 胃轻瘫 大鼠 

中图分类号

R2-03 

文献标志码

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgments

This work was supported by National Natural Science Foundation of China (国家自然科学基金项目, No. 81403487); Youth Fund of Hunan Provincial Education Department (湖南省教育厅青年基金, No. 14B128); Open Fund Project of Hunan University Innovation Platform (湖 南省高校创新平台开放基金项目, No.12K088).

References

  1. [1]
    Horváth VJ, Izbéki F, Lengyel C, Kempler P, Várkonyi T. Diabetic gastroparesis: functional/morphologic background, diagnosis, and treatment options. Curr Diab Rep, 2014, 14(9): 527.CrossRefPubMedGoogle Scholar
  2. [2]
    Kim SJ, Park JH, Song DK, Park KS, Lee JE, Kim ES, Cho KB, Jang BK, Chung WJ, Hwang JS, Kwon JG, Kim TW. Alterations of colonic contractility in long-term diabetic rat model. J Neurogastroenterol Motil, 2011, 17(4): 372–380.CrossRefPubMedPubMedCentralGoogle Scholar
  3. [3]
    Kofod-Andersen K, Tarnow L. Prevalence of gastroparesisrelated symptoms in an unselected cohort of patients with type 1 diabetes. J Diabetes Complications, 2012, 26(2): 89–93.CrossRefPubMedGoogle Scholar
  4. [4]
    Kuwata H, Iwasaki M, Shimizu S, Minami K, Maeda H, Seino S, Nakada K, Nosaka C, Murotani K, Kurose T, Seino Y, Yabe D. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. Diabetologia, 2016, 59(3): 453–461.CrossRefPubMedGoogle Scholar
  5. [5]
    Wang P, Sun YF, Wang YH, Zhang YF. Progress in the integrative medical treatment of diabetic gastroparesis. Hebei Zhongyiyao Xuebao, 2011, 26(1): 43–44.Google Scholar
  6. [6]
    Zheng SL, Ge JY. Treatment efficacy of warming acupuncture on 40 cases of diabetic gastroparesis. Zhongguo Zhongyiyao Keji, 2010, 17(3): 247–248.Google Scholar
  7. [7]
    Wan QQ, He FE, Lin YP. Observation on indexes related to the evolution process of diabetic gastroparalysis rat models. Hunan Zhongyiyao Daxue Xuebao, 2014, 34(10): 6–10.Google Scholar
  8. [8]
    Li ZR. Experimental Acupuncture Science. Beijing: China Press of Traditional Chinese Medicine, 2007: 327–329.Google Scholar
  9. [9]
    Chen JZ, Yin JK, Hou CJ, Wang XP, Tang CH, Tang CH. Effect of Rhizoma Coptidis and Cortex Phellodendri on experimental model rat of deficient cold of spleen and stomach. Zhongguo Zhongyiyao Xiandai Yuancheng Jiaoyu, 2015, 13(10): 134–136.Google Scholar
  10. [10]
    Song GH, Sun W, Zhang P. Epidemiological study of type 2 diabetes in elderly people in Dalian. Zhongguo Tangniaobing Zazhi, 2002, 10(2): 112–113.Google Scholar
  11. [11]
    Cheng YZ, Tang Y, Li J. Progress in clinical research of diabetic gastroparesis. Shiyong Yiyuan Linchuang Zazhi, 2010, 7(2): 135–138.Google Scholar
  12. [12]
    Wang JN, Huang WJ, Cheng Y, Wang J, Hu MQ. Research progress of acupuncture in treating diabetic patients with DGP. Xiandai Zhongyiyao, 2012, 32(1): 80–82.Google Scholar
  13. [13]
    Xu Z, Kong Y, Yuan XD, Du GZ. Study on the modern application of acupoints of stomach in diabetic gastroparesis. Zhongyi Wenxian Zazhi, 2015, 3(3): 67–68.Google Scholar
  14. [14]
    Cao F, Li T, Shan CX, Ha LJ, Li YQ, Wang FC. Study of the acupoint selection rules to treat diabetic gastroparesis with acupuncture based on the literature analysis. Zhongguo Zhongyi Jichu Yixue Zazhi, 2016, 21(1): 110–112.Google Scholar
  15. [15]
    Huang TS, Shang YY, Guo ZP. Acupoint injection combined with Jianpi Guben Hewei Decoction in the treatment of diabetic gastroparesis clinical observation of 35 cases of patients with deficiency of spleen and stomach type. Liaoning Zhongyiyao Daxue Xuebao, 2015, 17(4): 80–83.Google Scholar
  16. [16]
    Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol, 2011, 9(1): 5–12.CrossRefPubMedGoogle Scholar
  17. [17]
    Yao DY, Liu F. Review of studies on pathogenesis of diabetic gastroparesis. Guoji Xiaohuabing Zazhi, 2011, 31(1): 16–18.Google Scholar
  18. [18]
    Mager U, Degenhardt T, Pulkkinen L, Kolehmainen M, Tolppanen AM, Lindström J, Eriksson JG, Carlberg C, Tuomilehto J, Uusitupa M; Finnish Diabetes Prevention Study Group. Variations in the ghrelin receptor gene associate with obesity and glucose metabolism in individuals with impaired glucose tolerance. PLoS One, 2008, 3(8): 2941.CrossRefGoogle Scholar
  19. [19]
    Trudel L, Tomasetto C, Rio MC, Bouin M, Plourde V, Eberling P, Poitras P. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol, 2002, 282(6): 948–952.CrossRefGoogle Scholar
  20. [20]
    Ma XB, Xu WH. Review of relationship between ghrelin and gastrointestinal diseases. Shijie Huaren Xiaohua Zazhi, 2013, 21(3): 239–243.Google Scholar
  21. [21]
    Xin FJ, Xu L. Study on the effects of ghrelin on intracellular calcium mobilization and its relationship with NO in guinea pig gastric antrum smooth muscle cells. Xiandai Shengwu Yixue Jinzhan, 2010, 10(2): 216–220.Google Scholar
  22. [22]
    Xu L, Sun XR, Han XH, Zhong F, Depoortere I, Peeters T. Expression of ghrelin in nervous system and its cytoprotective action in rats. Shijie Huaren Xiaohua Zazhi, 2006, 14(5): 752–757.Google Scholar
  23. [23]
    El-Salhy M, Rauma J. Low density of ghrelin cells in the oxyntic mucosa correlated to slow gastric emptying in patients with type 1 diabetes. Mol Med Report, 2009, 2(6): 893–896.CrossRefGoogle Scholar
  24. [24]
    Wo JM, Ejskjaer N, Hellström PM, Malik RA, Pezzullo JC, Shaughnessy L, Charlton P, Kosutic G, McCallum RW. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting: randomised clinical study subset data. Aliment Pharmacol Ther, 2011, 33(6): 679–688.CrossRefPubMedGoogle Scholar
  25. [25]
    Chen CY, Fujimiya M, Laviano A, Chang FY, Lin HC, Lee SD. Modulation of ingestive behavior and gastrointestinal motility by ghrelin in diabetic animals and humans. J Chin Med Assoc, 2010, 73(5): 225–229.CrossRefPubMedGoogle Scholar
  26. [26]
    Meyer C. Final answer: ghrelin can suppress insulin secretion in humans, but is it clinically relevant? Diabetes, 2010, 59(11): 2726–2728.Google Scholar

Copyright information

© Shanghai Research Institute of Acupuncture and Meridian and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Yan Peng (彭艳)
    • 1
  • Ya-ping Lin (林亚平)
    • 1
  • Feng-e He (贺凤娥)
    • 1
  • Quan-quan Wan (万荃荃)
    • 1
  • Wen Chen (陈文)
    • 1
  • Qin Liu (刘琴)
    • 1
  • Shou-xiang Yi (易受乡)
    • 1
  1. 1.Major Laboratory of Meridians and Viscera, Tertiary Laboratory of State Administration of Traditional Chinese Medicine, Institute of Acupuncture, Moxibustion and MassageHunan University of Chinese MedicineChangshaChina

Personalised recommendations